Somatostatin receptor scintigraphy in the initial staging of Hodgkin's disease

Br J Haematol. 1996 Apr;93(1):96-103. doi: 10.1046/j.1365-2141.1996.443986.x.

Abstract

Somatostatin receptor (SS-R) scintigraphy has been successfully used in the visualization of a variety of neuroendocrine tumours. In vitro studies have shown that SS-Rs are present in human malignant lymphomas. We conducted a prospective study in 56 consecutive untreated patients with histologically proven Hodgkin's disease (HD) and compared the results of SS-R scintigraphy with physical and radiological examinations as initial evaluation. SS-R scintigraphy was positive in 55/56 (98%) patients at sites of documented disease. In 20 patients SS-R scintigraphy disclosed lymphoma localizations not revealed following procedures of conventional staging. As a result in 12 patients (21%) SS-R scintigraphy produced a change of stage and in seven patients (13%) the additional information obtained from SS-R scintigraphy led to a change of treatment. SS-R scintigraphy failed to visualize sites of HD in four patients, mainly in the abdominal area. In three patients a false-positive result was obtained. These data show that SS-R scintigraphy provides an imaging technique that appears to visualize tumours in most patients with HD and may be clinically useful in the management of these patients.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Female
  • Hodgkin Disease / diagnostic imaging*
  • Hodgkin Disease / pathology
  • Humans
  • Lymph Nodes / diagnostic imaging*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prospective Studies
  • Radiography
  • Radionuclide Imaging
  • Receptors, Somatostatin / analysis*
  • Sensitivity and Specificity

Substances

  • Receptors, Somatostatin